灯盏生脉胶囊佐治缺血性脑卒中的Meta分析
发布时间：2019-05-14 11:09
【摘要】：目的系统评价灯盏生脉胶囊佐治缺血性脑卒中的临床疗效及其二级预防作用。方法计算机检索Pubmed、EMbase、Cochrane Library和CNKI、CBM、VIP、Wanfang Data,检索时限为建库至2016年2月,同时手工检索相关杂志和网页搜索谷歌学术,纳入关于灯盏生脉胶囊佐治缺血性脑卒中的随机对照试验。由2名研究者独立地按照纳入和排除标准筛选文献、提取相关数据并进行质量评价,采用Rev Man5.3对结局指标进行meta分析。结果共纳入文献18篇,患者4 416例。Meta分析结果显示,与对照组相比,试验组能降低脑卒中复发率[RR=0.53,95%CI(0.39,0.71),P0.000 1]和病死率[RR=0.28,95%CI(0.11,0.68),P0.005],且在临床疗效[RR=1.22,95%CI(1.15,1.29),P0.000 01]及日常生活能力[MD=9.19,95%CI(3.41,14.98),P=0.002]上要优于对照组;在残障功能改善程度[MD=?0.04,95%CI(?0.16,0.07),P=0.47][RR=1.11,95%CI(0.89,1.40),P=0.35]和不良反应发生率[RR=0.68,95%CI(0.34,1.37),P=0.29]上2组间无明显差异。结论灯盏生脉胶囊佐治缺血性脑卒中与常规治疗相比能够降低脑卒中复发率和病死率,且在临床疗效和日常生活能力上要优于常规治疗。在残障功能改善程度上两者无明显差别。灯盏生脉胶囊联合常规治疗未明显增加不良反应发生。
[Abstract]:Objective to systematically evaluate the clinical efficacy and secondary preventive effect of Dengzhan Shengmai capsule in the treatment of ischemic stroke. Methods the time limit of computer retrieval of Pubmed,EMbase,Cochrane Library and CNKI,CBM,VIP,Wanfang Data, was from the construction of database to February 2016. At the same time, related magazines and web pages were searched manually for Google academic search. A randomized controlled trial on the treatment of ischemic stroke with Dengzhan Shengmai capsule was included. Two researchers independently selected the literature according to the inclusion and exclusion criteria, extracted the relevant data and evaluated the quality. Meta analysis of the outcome index was carried out by Rev Man5.3. Results A total of 18 articles and 4416 patients were included in the literature. Meta-analysis showed that compared with the control group, the experimental group could reduce the recurrence rate of stroke [RR=0.53,95%CI (0.39, 0.71). P0.000 1] and mortality [RR=0.28,95%CI (0.11, 0.68), P0.005], and clinical efficacy [RR=1.22,95%CI (1.15, 1.29), P0.000 01] and ability of daily living [MD=9.19,95%CI (3.41, 14.98), P 鈮，
本文编号：2476663
[Abstract]:Objective to systematically evaluate the clinical efficacy and secondary preventive effect of Dengzhan Shengmai capsule in the treatment of ischemic stroke. Methods the time limit of computer retrieval of Pubmed,EMbase,Cochrane Library and CNKI,CBM,VIP,Wanfang Data, was from the construction of database to February 2016. At the same time, related magazines and web pages were searched manually for Google academic search. A randomized controlled trial on the treatment of ischemic stroke with Dengzhan Shengmai capsule was included. Two researchers independently selected the literature according to the inclusion and exclusion criteria, extracted the relevant data and evaluated the quality. Meta analysis of the outcome index was carried out by Rev Man5.3. Results A total of 18 articles and 4416 patients were included in the literature. Meta-analysis showed that compared with the control group, the experimental group could reduce the recurrence rate of stroke [RR=0.53,95%CI (0.39, 0.71). P0.000 1] and mortality [RR=0.28,95%CI (0.11, 0.68), P0.005], and clinical efficacy [RR=1.22,95%CI (1.15, 1.29), P0.000 01] and ability of daily living [MD=9.19,95%CI (3.41, 14.98), P 鈮，
本文编号：2476663
本文链接：https://www.wllwen.com/yixuelunwen/shenjingyixue/2476663.html
最近更新
教材专著
